Ahmad Iqbal, MD
Advanced Heart Failure and Transplant Cardiology · Shenandoah, TXNPI 1174753917
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $81,033 of the $94,524 with a category attached, or 85.7%. 29 manufacturers reported payments, led by Boehringer Ingelheim at 46.2% of the total.
Across 341 payments — averaging $277.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$44K
- Lilly USA, LLC$32K
- Pfizer$9K
- Abbott$6K
- Boston Scientific$1K
- Novartis$666
- plus $2K from 23 others
What the payments were for
- Consulting fees$3,3003%
- Speaking & faculty fees$81,03386%
- Travel & lodging$3780%
- Food & beverage$9,81110%
- Education$30%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 65 | $43,665 |
| Lilly USA, LLC | 35 | $31,752 |
| Pfizer | 16 | $8,737 |
| Abbott | 70 | $6,399 |
| Boston Scientific | 29 | $1,047 |
| Novartis | 50 | $666 |
| Biotronik Inc. | 4 | $317 |
| Atricure, Inc. | 2 | $274 |
| Abiomed | 4 | $234 |
| Amgen | 16 | $219 |
| Impulse Dynamics (USA) Inc. | 4 | $169 |
| Merck | 8 | $145 |
| Bayer | 1 | $142 |
| Cvrx, Inc. | 2 | $105 |
| E.r. Squibb & Sons, L.L.C. | 5 | $97 |
| Alnylam Pharmaceuticals Inc. | 4 | $85 |
| Johnson & Johnson | 4 | $71 |
| Actelion Pharmaceuticals US, Inc. | 3 | $63 |
| United Therapeutics Corporation | 4 | $60 |
| AstraZeneca | 3 | $46 |
| Novo Nordisk | 2 | $35 |
| Inari Medical, Inc. | 2 | $30 |
| Baxter Healthcare | 1 | $30 |
| Akcea Therapeutics, Inc. | 1 | $29 |
| Shockwave Medical, Inc | 1 | $24 |
| Biosense Webster, Inc. | 1 | $23 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $22 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $20 |
| Medtronic | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$72,299
- VYNDAQEL$8,499
- CARDIOMEMS$2,337
- CardioMEMS HF System$1,971
- MitraClip System$310
- HeartMate$252
- Watchman$187
- ATRICLIP LAA EXCLUSION SYSTEM$175
- Kerendia$142
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$141
- HeartMate 3 Left Ventricular Dev$136
- Rivacor 7 DR-T$125
- Acticor 7 VR-T DX$125
- Zero Gravity$125
- BioMonitor$125
- MitraClip$115
- WATCHMAN Access System$114
How this compares
$94,524 in reported general payments places this provider in the 80th percentile of 75 advanced heart failure and transplant cardiology providers in Texas.
See all advanced heart failure and transplant cardiology providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 43 | $1,138,793 |
| VyndaqelTafamidis Meglumine | 12 | $269,336 |
| EliquisApixaban | 165 | $176,823 |
| EntrestoSacubitril/Valsartan | 108 | $145,400 |
| JardianceEmpagliflozin | 104 | $124,934 |
| XareltoRivaroxaban | 22 | $30,909 |
| FarxigaDapagliflozin Propanediol | 23 | $22,878 |
| Bumetanide | 62 | $2,802 |
| Metoprolol Succinate | 140 | $2,141 |
| Ranolazine ErRanolazine | 32 | $1,974 |
| Carvedilol | 165 | $1,502 |
| Atorvastatin Calcium | 152 | $1,340 |
| Amiodarone Hcl | 40 | $1,337 |
| Nifedipine ErNifedipine | 18 | $997 |
| Potassium Chloride | 56 | $964 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Vyndaqel, Eliquis | $8,737 | $1,584,953220 claims |
| NovartisEntresto | $666 | $145,400108 claims |
| Boehringer IngelheimJardiance | $43,665 | $124,934104 claims |
| Johnson & JohnsonXarelto | $71 | $30,90922 claims |
| AstraZenecaFarxiga | $46 | $22,87823 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 75 advanced heart failure and transplant cardiology providers in Texas.
Other advanced heart failure and transplant cardiology in Shenandoah
- Robert GottliebDallas$717K
- Albert HicksTemple$613K
- Allen AndersonSan Antonio$413K
- Martin BerkDallas$379K
- Aasim AfzalPlano$336K
- Kunjan BhattAustin$324K
- Barry TrachtenbergHouston$306K
- Shelley HallDallas$254K
- Arvind BhimarajHouston$216K
- Jerome ThomasAustin$182K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.